Meet Cardiovascular Diabetology's Associate Editor of the Year - Dr. Jens Kroll

Dr. Jens Kroll has recently been awarded with Cardiovascular Diabetology’s annual Associate Editor Award. In this Q&A we find out what Dr. Jens Kroll likes about the work as Associate Editor and what impact it has made for his own work.
Meet Cardiovascular Diabetology's Associate Editor of the Year - Dr. Jens Kroll
Like

Share this post

Choose a social network to share with, or copy the URL to share elsewhere

This is a representation of how your post may appear on social media. The actual post will vary between social networks

Congratulations on winning the first edition of Cardiovascular Diabetology’s Associate Editor Award! How does it feel to win the first edition?

Thank you for selecting me for this award. I'm very happy and proud that the Editor-in-Chief of Cardiovascular Diabetology appreciate my work for the journal and the way I respond to manuscripts.  

But first, please introduce yourself.

 I studied biochemistry at the Martin-Luther University Halle/Wittenberg, Germany, and received my graduate and postdoctoral training in angiogenesis and vascular biology research at the University of Ulm, Germany, and at the University of Texas, Southwestern Medical Center in Dallas, TX, USA. Since 2007 I've been working at the University of Heidelberg, Medical Faculty Mannheim. I do basic research and run a lab with a couple of PhD/MD students, I teach physiology to medical students and I'm the scientific director of the graduate school STMM (School of Translational Medicine Mannheim) at my faculty.

Why did you choose this research area? 

Based on my research experience in angiogenesis and vascular biology with a focus on basic mechanisms, I believe it is now important to better understand how blood vessels contribute to disease processes with a special focus on metabolism. Microvascular diseases such as diabetic retinopathy, diabetic nephropathy and diabetic neuropathy are a major burden for type 2 diabetic patients with limited therapeutic options. Reactive carbonyl species are formed spontaneously in our bodies, and as long as they are detoxified by the appropriate enzyme systems, we are protected from the reactive carbonyl stress that can lead to many diseases, including diabetes and its microvascular complications. My lab studies these enzyme systems and in recent years we have found that the loss of specific detoxifying enzyme systems for reactive carbonyls can lead to the formation diabetes and the hallmarks of diabetic retinopathy and diabetic nephropathy. We are using the zebrafish model because of its excellent imaging capabilities and the fact that diabetic zebrafish can overcome existing limitations of other animal models in diabetes research.

What is your vision? What you’d like to achieve with your research?

I want to better understand the interplay between the different reactive carbonyls in the development of diabetes and its microvascular complications. I aim to identify and understand some of their cellular and molecular targets and how these modifications can lead to disease processes. The perspective is to determine reactive carbonyls in patients with pre-diabetes and diabetes, which may help to predict disease progression in these patients, and eventually to develop drugs that may delay or even reverse the onset of diabetes and its organ complications.

How does a typical working day look like for you?

I spent 50% of my working day on research, 30% on teaching and 20% on organizational matters. This includes discussing data with my students, lab meetings, drafting, writing and proofreading manuscripts, writing grant proposals, giving talks, reviewing manuscripts and grant applications. I manage scientific collaborations and I’m the head of the zebrafish core facility at the Medical Faculty Mannheim. I also manage animal welfare considerations and safety issues in my lab. In my faculty, I co-direct our graduate school for MD and PhD students and I’m an active member of the PhD committee. I also teach physiology to medical students and act as an oral examiner.

You have been working as Associate Editor for Cardiovascular Diabetology since November 2022, what do you like about your work as Associate Editor for the journal?

Working for Cardiovascular Diabetology gives me a great insight how a scientific journal works, the opportunity to read unpublished work, provide constructive and fair criticism and support the authors of submitted manuscripts.

Now that you’ve worked for over 2 years on the journal, is the work how you expected it before or did you have any surprises or challenges? 

The work is mostly as expected and I like the professionalism of Cardiovascular Diabetology. The challenge is to find qualified reviewers who respond in a timely manner, and I'm still surprised that some reviewers agree to review a manuscript but then fail to provide a report.  

Has the journal work had any impact on your research or views?

It has broadened my perspective on my own research questions.

If you are interested in reading more about Cardiovascular Diabetology's Associate Editor Award, visit Cardiovascular Diabetology's homepage

Please sign in or register for FREE

If you are a registered user on Research Communities by Springer Nature, please sign in

Follow the Topic

Diabetes
Life Sciences > Health Sciences > Clinical Medicine > Diseases > Diabetes
Angiogenesis
Life Sciences > Health Sciences > Clinical Medicine > Cardiology > Cardiovascular Physiology > Angiogenesis

Related Collections

With collections, you can get published faster and increase your visibility.

Cardiometabolic HFpEF with focus on type 2 diabetes mellitus

This collection aims to highlight the complex interplay between metabolic factors and heart failure with preserved ejection fraction (HFpEF), particularly focusing on type 2 diabetes (T2D). Described as the “single largest unmet need in cardiovascular medicine”, HFpEF has come to represent more than half of all new heart failure diagnoses and associates with a poor 5-year prognosis (40% mortality rate) despite optimal medical treatment. Obesity and diabetes-related HFpEF, also known as cardiometabolic HFpEF (HFpEF), is the most prevalent HFpEF phenotype and its incidence is expected to increase exponentially in decades to come. The presence of T2D contributes to disease development and progression through mechanisms such as insulin resistance, chronic inflammation, endothelial dysfunction, immune dysregulation and myocardial fibrosis. This collection welcomes original articles, meta-analyses and review articles that explore a range of topics from mechanistic studies and therapeutic targets to clinical aspects, pharmacology, epidemiology, and advanced imaging techniques. Our goal is to provide a comprehensive and state-of-the-art overview of this critical area, highlighting the multifaceted nature of HFpEF in cardiometabolic health. This collection aims to bridge the gap between research and clinical application, offering invaluable knowledge for both healthcare professionals and researchers dedicated to improving cardiovascular health. Specifically, the issue will cover the following topics: • Molecular mechanisms of diabetic HFpEF • HFpEF and cardiometabolic disease • Prevalence, risk prediction and prognosis of diabetic HFpEF • Diabetes and hypertension in HFpEF • GLP1-RA and SGLT2i in HFpEF • Artificial intelligence-based approaches in diabetic HFpEF • Sex and gender in diabetic HFpEF • Comorbidities in diabetic HFpEF

Publishing Model: Open Access

Deadline: Ongoing

Perivascular adipose tissue: friend or foe in cardiometabolic disorders

Perivascular adipose tissue (PVAT) has been identified as a key mediator in the maintenance of vascular homeostasis since the groundbreaking work of Soltis and Cassis (1991). PVAT present in the majority of blood vessels throughout the body (with the exception of cerebral and pulmonary arteries), demonstrates regional variations and heterogeneity along the vascular network. Furthermore, PVAT comprises diverse cell types beyond adipocytes. The interconnection between PVAT and blood vessel wall cells is vital for normal vascular function. Recently considered a biomarker and target in pathologic conditions such as atherosclerosis PVAT changes its phenotype under pathologic conditions such as obesity and diabetes. Aging is another factor that modifies this tissue. Hence, the aims of this collection are to highlight: 1) The importance of PVAT in cardiovascular disease, whether in the presence or absence of diabetes. 2) The involvement of PVAT and its heightened impact on arterial stiffness during aging and various diseases. 3) The translational potential of PVAT as an innovative therapeutic target in clinical contexts. For this collection, papers on diabetes, cardiovascular disease, aging, perivascular adipose tissue, obesity, arterial stiffness, gut microbiome, hypercholesterolemia, cholesterol, heart failure, exercise, nutraceuticals, diet, ketogenic diet, oxidative stress, and inflammation are welcome. Along these lines reinforcing the role and mechanisms of PVAT in cardiometabolic diseases is imperative and will help to explain heterogeneity in different vascular beds. Furthermore, exploration into the impact of perivascular adipose tissue (PVAT) on arterial stiffening remains in its early stages, providing limited understanding of this aspect of arterial health. Studies conducted on aging, obesity, and heart failure in preclinical models have directly shown that PVAT promotes or contributes to arterial stiffness. These findings also offer preliminary insights into potential novel targets for intervention. However, there are few interventions that effectively modify the PVAT phenotype to reduce arterial stiffness. A practical approach to bridging preclinical discoveries with clinical applications and establishing PVAT as a therapeutic target for arterial de-stiffening and overall arterial health involves utilizing clinical imaging techniques. For this collection all types of articles are welcome (research articles, commentaries, review articles…).

Publishing Model: Open Access

Deadline: Ongoing